569 / 1835
No mention so far of capitalising
our insights from biology……
Adapted from Lossos and Morganstein JCO 2006;24:995
►
If we can get the biomarkers right then will be
able to identify patients that may benefit from
intensification or specific targeted therapies.
Cell cycle regulation
p53
p16
p27
Cyclin D2
Ki67
c-myc
Apoptosis related
Bcl-2
B-cell differentiation
Bcl-6
CD10
CD5
FoxP1
CD21
Adhesion molecules
ICAM-1
Microenvironment
VEGF
CD40
HIF-1α